Biomarkers for Chronic Pain: Significance and Summary of Recent Advances.

Authors:
Eldabe S; Obara I; Panwar C; Caraway D.

Journal:
Pain Res Manag

Publication Year: 2022

DOI:
10.1155/2022/1940906

PMCID:
PMC9663208

PMID:
36385904

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pain Res Manag

Abbreviation: Pain Res Manag

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Psychophysiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A Comparison of the Effects of Acupressure and Music on Venipuncture Pain Intensity in Children: A …
Daihimfar F; Babamohamadi H; Ghorbani R. (2024) - Transparency Score: 4/6
How Do We Treat Children with Anterior Cutaneous Nerve Entrapment Syndrome and Is the Biopsychosoci…
Top APC; de Leeuw TG; Bramer WM and 3 more (2024) - Transparency Score: 2/6
Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal…
Kaijankoski H; Nissen M; Ikäheimo TM and 3 more (2024) - Transparency Score: 3/6
NGF Signaling Exacerbates KOA Peripheral Hyperalgesia via the Increased TRPV1-Labeled Synovial Sens…
Liu Z; Li M; Zhang L and 5 more (2024) - Transparency Score: 3/6
Role of TNF<i>-α</i> in the Pathogenesis of Migraine.
Sudershan A; Sudershan S; Sharma I and 3 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest S.E. is a paid consultant for Medtronic, Boston Scientific, Mainstay Medical and has received research funding from Medtronic Boston Scientific and the National Institute for Health Research. C.P. is a paid consultant for medical writing for Nevro. D.C., is an employee of Nevro Corp. I.O., and has received research funding from Medtronic and Saluda Medical."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025